Hypopigmented Mycosis Fungoides in Type V Skin: A Report of 5 Cases

Table 1

Hypopigmented mycosis fungoides: patient demographics, clinical manifestations, and response to therapy.

Patients’ index number	Age at diagnosis/onset (years)	Gender	Initial diagnosis	Site of skin involvement	% of skin involvement at the time of diagnosis	lymph nodes (LN), liver (Liv), spleen (Sp)	Stage at diagnosis	Previous treatments	Type of therapy given	Response to therapy
1 (Figure 1)	13/10	F	PV	Both lower and upper limbs, vitiligo-like lesions on buttocks	30%	L/axillary LN 0.5–1 cm diameter	1B	Topical antifungal	NB-UVB 32 (3x/wk)	CR
2 (Figure 2)	29/26	M	PV	All 4 limbs, buttock, a few patches on trunk	40%	None	1B	Topical antifungal	PUVA 36 (2x/wk)	CR
3 (Figure 3)	11/08	M	Eczema, vitiligo	Vitiligo-like patches on buttocks	<10%	None	1A	Topical steroids, 10% coal tar lotion and sun light exposure	Potent topical steroids daily for 12 months	PR
4 (Figure 4)	30/27	F	PV, PMH	All 4 limbs flexure aspect, anterior and back of trunk, breast	30%	None	1B	Topical antifungal	NB-UVB 36 (3x/wk)	CR
5 (Figure 5)	29/24	F	PV, vitiligo	Trunk, all 4 limbs	40%	None	1B	Topical antifungal	NB-UVB 32 (3x/wk)	PR

M—male, F—female, MF—mycosis fungoides, NB-UVB—narrowband ultraviolet B, PUVA—psoralen plus ultraviolet A, PV—Pityriasis versicolor, PLC—pityriasis lichenoides chronica, PMH—progressive macular hypomelanosis, NR—no clinical response, PR—partial clinical response, CR—complete clinical response.